Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 4.95Ind-Swift Laboratories exhibits a mixed financial profile. Profitability stands out as a key strength, driven by healthy margins and returns on capital. Solvency is also strong, indicating a low reliance on debt. Liquidity shows potential, supported by current and quick ratios, but is offset by a low operating cash flow ratio. However, the company has faced major issues in growth and inefficieny. Capital expenditure is low which is affecting company's growth. Overall, Ind-Swift Laboratories demonstrates solid profitability and solvency, but needs to address issues in growth and financial management to achieve a more balanced and robust financial performance.
Health Score : 4.95Ind-Swift Laboratories exhibits a mixed financial profile. Profitability stands out as a key strength, driven by healthy margins and returns on capital. Solvency is also strong, indicating a low reliance on debt. Liquidity shows potential, supported by current and quick ratios, but is offset by a low operating cash flow ratio. However, the company has faced major issues in growth and inefficieny. Capital expenditure is low which is affecting company's growth. Overall, Ind-Swift Laboratories demonstrates solid profitability and solvency, but needs to address issues in growth and financial management to achieve a more balanced and robust financial performance.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
75.29
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
77.18
P/B RATIO
2.32
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
5.02
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
34.57
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹368.15 as on Sep 1, 2026.
Growth Score : 2.00The company is witnessing negative growth in revenue, operating profit, EPS, assets and net income. Revenue and operating profit growth have declined, reflecting challenges in expanding sales and maintaining profitability. A decline in asset growth indicates reduced investment in new opportunities or contraction of business activities. This could be due to various factors, including market conditions, competition, or internal inefficiencies.
Revenue Growth RatePoorOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RatePoorNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 16.61 | 16.17 | 41.59 | -67.12 | 14.06 |
| Operating Profit Growth Rate | 10.38 | 13.37 | 33.62 | -106.21 | 336.84 |
| Earnings Per Share (EPS) Growth | 32.08 | 2338.89 | 1031.27 | -54.68 | -88.46 |
| Asset Growth Rate | -0.94 | 1.28 | -19.96 | -1.51 | 16.34 |
| Net Income Growth Rate | 33.33 | 2500 | 1022.92 | -53.62 | -83.6 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
No Peer Data Is Available at This Moment.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Quarterly Report⬤31st Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
Ind-Swift Laboratories Ltd is a prominent Indian pharmaceutical company focused on manufacturing Active Pharmaceutical Ingredients (APIs) and finished dosage forms. It specializes in diverse therapeutic areas like anti-histaminic, anti-fungal, and anti-bacterial. The company operates globally, leveraging its manufacturing capabilities for domestic and international markets.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Ind-Swift Laboratories Ltd's P/E ratio (TTM) is 75.29, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Ind-Swift Laboratories Ltd's P/B ratio is 2.32, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Ind-Swift Laboratories Ltd's P/S ratio is 5.02, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Ind-Swift Laboratories Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Ind-Swift Laboratories Ltd's EV/EBITDA ratio is 34.57.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Ind-Swift Laboratories Ltd's ROE is 2.96%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Ind-Swift Laboratories Ltd's ROA is 2.69%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Ind-Swift Laboratories Ltd's ROCE is 5%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Ind-Swift Laboratories Ltd's operating margin is 7.02%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Ind-Swift Laboratories Ltd's net margin is 6.40%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Ind-Swift Laboratories Ltd's current ratio is 4.01.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Ind-Swift Laboratories Ltd's debt-to-equity ratio is 0.01.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Ind-Swift Laboratories Ltd's interest coverage ratio is 50.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Ind-Swift Laboratories Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Ind-Swift Laboratories Ltd's EPS is -88.46.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹368.15. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1986
Headquarters: Chandigarh, Punjab
Core Offerings: Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms, Contract Research and Manufacturing Services (CRAMS)
Stock Listing: NSE (INDSWFTLAB), BSE (532305)
Promoter: Ind-Swift Group (Dr. Gopal Munjal)
Ind-Swift Laboratories Ltd was incorporated in 1986. The company established its first manufacturing facility and commenced production of Active Pharmaceutical Ingredients (APIs) in the mid-1990s. Over the years, it significantly expanded its manufacturing capacities and diversified its product portfolio to include various therapeutic segments and finished dosage forms. Ind-Swift has grown into a key player in the API and CRAMS space, catering to both Indian and global pharmaceutical markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceuticals | 100% | N/A (company reports consolidated EBITDA) |
Active Pharmaceutical Ingredients (APIs): Manufactures a diverse portfolio of APIs for various therapeutic categories, including anti-histaminic, anti-depressant, anti-bacterial, and anti-fungal, serving both domestic and international markets.
Finished Dosage Forms (FDFs): Produces a range of finished formulations across different therapeutic segments, supplied to regulated and semi-regulated markets globally.
Contract Research and Manufacturing Services (CRAMS): Offers custom synthesis and manufacturing services, leveraging its expertise and facilities for global pharmaceutical partners.
Dr. Gopal Munjal: Chairman & Managing Director. A seasoned entrepreneur and visionary, Dr. Munjal has been instrumental in establishing and guiding Ind-Swift Laboratories' growth in the pharmaceutical sector.
['Ind-Swift Pharmaceuticals Limited', 'Ind-Swift Capital Private Limited', 'Ind-Swift Health Sciences Private Limited']
Rights Issue in 2021 (Right Shares issued at ₹85 per share in the ratio of 3:4). No major recent M&A on record.
The Ind-Swift Laboratories Ltd share price today is ₹368.15 on NSE (INDSWFTLAB), as of 26 Sept 2026.
As of 26 Sept 2026, Ind-Swift Laboratories Ltd share price is ₹368.15, with previous close ₹368.15. Today's range is ₹368.15 to ₹368.15. The 52-week range is ₹87.15 to ₹419.80.
As of today, Ind-Swift Laboratories Ltd's market cap is ₹3,217.63 crore (Small Cap).
Ind-Swift Laboratories Ltd's current P/E ratio is 75.29, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 34.50.
Ind-Swift Laboratories Ltd's current P/B ratio is 2.32.
Ind-Swift Laboratories Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Ind-Swift Laboratories Ltd's EPS (TTM) is ₹-88.46.
Ind-Swift Laboratories Ltd is a prominent Indian pharmaceutical company focused on manufacturing Active Pharmaceutical Ingredients (APIs) and finished dosage forms. It specializes in diverse therapeutic areas like anti-histaminic, anti-fungal, and anti-bacterial. The company operates globally, leveraging its manufacturing capabilities for domestic and international markets.
Ind-Swift Laboratories Ltd is promoted by Ind-Swift Group (Dr. Gopal Munjal), holding 42.99% as of 26 Sept 2026.
Ind-Swift Laboratories Ltd is listed on NSE (INDSWFTLAB) and BSE (532305). Its next quarterly results are expected on August 2024.
Gross Profit Margin
